2019
DOI: 10.1038/s41380-019-0555-5
|View full text |Cite
|
Sign up to set email alerts
|

Identifying biological markers for improved precision medicine in psychiatry

Abstract: he is involved in clinical trials conducted by Eli Lilly, Novartis, and Shire and Viforpharma; he received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. Dr. Barker has received honoraria from General Electric Healthcare for teaching on scanner programming courses and acts as a consultant for IXICO. The other authors report no biomedical financial interests or potential conflicts of interest. Disclosures Dr. Banaschewski served in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
39
0
3

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
3
1

Relationship

3
7

Authors

Journals

citations
Cited by 52 publications
(43 citation statements)
references
References 70 publications
1
39
0
3
Order By: Relevance
“…Therefore, future replications should also be carried out outside of Europe, requiring careful harmonization of clinical tools and paradigms. As recently reported [ 150 ], the IMAGEN study has aligned itself with other global neuroimaging-genetics adolescent cohorts that will further enhance and clarify the work presented here.…”
Section: Discussionsupporting
confidence: 56%
“…Therefore, future replications should also be carried out outside of Europe, requiring careful harmonization of clinical tools and paradigms. As recently reported [ 150 ], the IMAGEN study has aligned itself with other global neuroimaging-genetics adolescent cohorts that will further enhance and clarify the work presented here.…”
Section: Discussionsupporting
confidence: 56%
“…The difficulty is compounded by the lack of reliable biological markers in psychiatric evaluation, which makes it difficult to quantify any improvement after hospitalization, or in general after hospital or out-of-hospital pharmacotherapy and psychotherapy interventions [42]. The availability of biomarkers is going to increase in the near future as a great amount of research is already oriented in this direction [43].…”
Section: Discussionmentioning
confidence: 99%
“…1a). Precision medicine does not only apply to pharmacological treatments, but also to psychological interventions for various chronic diseases [20]. Given that no prognostic factors, patient characteristics, and/or symptom characteristics for adults with subjective idiopathic tinnitus have been found to in uence the nal treatment outcomes, we reasoned that genetic information can be useful for the formulation of a more standardized cognitive/behavioral approach.…”
Section: Application Of the Genotype-based Algorithm Improves The Outmentioning
confidence: 99%